Earnings Releases·Nov 4, 2026, 4:11 PM ET

Alpha Teknova, Inc. — Third Quarter 2026 Earnings Summary

Q3 2026 revenue reached $12.7 million, a 22% year-over-year increase driven by a 9% rise in Lab Essentials and an 86% surge in Clinical Solutions, while net loss narrowed to $3.5 million ($0.06/share) from $4.3 million ($0.08/share) in the prior year.
Gross margin expanded to 38.0% from 30.7% and Adjusted EBITDA improved to negative $1.0 million from negative $1.6 million, supported by reduced operating cash outflow to $1.3 million and free cash outflow of $1.4 million.
Full-year 2026 revenue guidance was raised to $46–$48 million, with management reaffirming an expectation for total free cash outflow to remain under $8 million.
The company closed a public offering on October 22, 2026, raising $46.0 million in gross proceeds ($42.9 million net), bringing total cash and short-term investments to $16.6 million against $13.2 million in borrowings.
Strategic growth was supported by the launch of the Fill-Tek Dispensing System and increased purchasing activity from small and mid-sized biotech customers, signaling early signs of market recovery.